[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-360858-en":3,"detail-sidebar-cat-0-en-105":51,"doc-seo-360858-105":99},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"doc_content":15,"file_id":16,"file_url":17,"file_type":18,"file_size":19,"view_count":20,"is_deleted":4,"is_public":21,"is_downloadable":21,"audit_status":21,"page_count":22,"language":23,"language_code":24,"site_id":25,"html_lang":24,"table_of_contents":26,"faqs":27,"seo_title":28,"seo_description":14,"update_tm":29,"read_time":30,"preview_page_count":31,"preview_urls":32},360858,5909892210082,"Well Done","https://ap-avatar.wpscdn.com/avatar/56001069da27c9f41e8?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789614185077863061",8,"Research & Report","Preclinical proof of concept for a personalized SNAP™-TIL (Specific Neo-Antigen Peptides-TIL) therapy platform","Tumor-infiltrating lymphocyte (TIL) therapy shows promise in melanoma but needs optimization for broader efficacy because neoantigen-reactive T cells are often rare and exhausted in less immunogenic cancers. The study evaluates a personalized neoantigen pipeline using SNAP™ technology, combining computational modeling with PepSeq to validate neoantigens by patient-specific HLA class II binding. SNAP-TIL products enriched for predefined immunogenic neoantigens show enhanced efficacy and selectivity versus rapid expansion alone, with tumor growth inhibition in melanoma and pancreatic xenograft models.","RESEARCH ARTICLE     \nPreclinical proof of concept for a personalized SNAP™-TIL (Specific NeoAntigen Peptides-TIL) therapy platform  \nTithi Ghosh Haldera, b , Erin Kelleyb, Jorge Soria-Bustosb, Trason Thodea, b, Serina Nga, b,  \nTaylor Bargenquasta, Alexis Westona, b, Ryan Rodriguez del Villarb, Mohan Kaadigea, b, Erkut Borazancia, Michael Gordona, Justin Mosera, Frank Tsaia, Saul J. Pricemanc, Stephen J. Formanc, Yan Xingd, John A. Altinb, Raffaella Soldia, b and Sunil Sharmaa, b  \naCenter for Translational Science, HonorHealth Research Institute, Scottsdale, AZ, USA; bTranslational Genomics Research Institute (TGen), Phoenix, AZ, USA; cDepartment of Hematology and Hematopoietic Cell Transplantation and T Cell Therapeutics Research Laboratories, City of Hope, Duarte, CA, USA; dDepartment of Medical Oncology, City of Hope National Medical Center, Duarte,  \nCA, USA  \nABSTRACT  \nTumor-infiltrating lymphocyte (TIL) therapy, which involves extracting, expanding, andreinfusing immune cells to target cancer cells, has shown promise in melanoma treatment, but requires optimization for broader efficacy. The success of TIL therapy depends on the recognition of tumor-associated antigens, but neoantigen-reactive Tcells are often rare and exhausted in less immunogenic malignancies. Isolating T cells enriched in neoantigen reactivity prior to in vitro expansion and reinfusion may improve the response rates. To this end, our proprietary Specific Neo-Antigen Peptides (SNAP™) technology platform improves the accuracy of neoantigen prediction and validation by combining advanced computational modelling and PepSeq, a high-throughput screen for the physical credentialing of putative neoantigens based on their affinity to bind patient-specific HLA class II proteins. This approach allows for the education and enrichment of TILs (SNAP-TILs) with personalized, predefined, highly immunogenic neoantigens prior to expansion. Using the SNAP platform, we consistently achieved, on average, a SNAP-TIL product comprising 96% CD3+ cells, with a mixture of 75% effector and 23% central memory cells. SNAP-TILs exhibited greater efficacy and selectivity in immune infiltration than TIL, which was expanded by the rapid expansion protocol alone using ex vivo models. SNAP-TIL was also reactive in highly and poorly immunogenic tumors, with 70% and 50% tumor growth inhibition in melanoma and pancreatic patient-derived xenograft models, respectively. This study demonstrates the novel benefit of our Personalized Neoantigen Pipeline approach, potentially providing a durable antitumor immune response for a larger proportion of cancer patients.  \nARTICLE HISTORY  \nReceived 29 May 2025 Revised 5 May 2026 Accepted 31 May 2026  \nKEYWORDS  \nAdoptive cell therapy; immunotherapy; PepSeq; neoantigens; SNAP-TIL; tumor-infiltrating lymphocytes  \nIntroduction  \nThe development of adoptive cell therapies (ACT) in solid tumors has lagged behind hematologic cancers for many reasons, including tumor heterogeneity, paucity of tumor-specific neoantigens, and possessing an immunosuppressive tumor microenvironment (TME) . Unlike CAR T or other cell therapies, adoptive tumor-infiltrating lymphocyte (TIL) therapy has achieved promising results in solid tumors. It has sometimes generated complete responses in patients who have failed first-line therapies.1-3 Recently, the FDA approved Iovance's Lifileucel, an unmodified but in vitro expanded TIL, to treat unresectable or metastatic melanoma. TIL therapy has distinct advantages over other cell therapies in treating solid tumors. TILs are polyclonal cells with multiple T cell receptors (TCR) derived directly from the tumor and can recognize a wide range of tumor-associated antigens (TAA), whereas CAR T cells require genetic engineering to recognize one or occasionally two neoantigens on tumor cells.4 Due to tumor heterogeneity  \nCONTACT Sunil Sharma  [ssharma@honorhealth.com](ssharma@honorhealth.com); Raffaella Soldi  rsoldi@honorhealth.com  Cen","cbCainCUKQf5InVp","https://ap.wps.com/l/cbCainCUKQf5InVp","pdf",3910689,10,1,18,"English","en",105,"# Abstract\n# Introduction\n# Article information\n## Received/Revised/Accepted\n## Keywords","[{\"question\":\"What problem does the personalized SNAP™-TIL approach aim to solve in TIL therapy?\",\"answer\":\"TIL responses depend on neoantigen recognition, but neoantigen-reactive T cells can be rare and exhausted in less immunogenic tumors. SNAP™ aims to improve enrichment for reactive neoantigens before expansion and reinfusion.\"},{\"question\":\"How does SNAP™ technology validate and enrich neoantigen-specific TILs?\",\"answer\":\"SNAP™ combines advanced computational modeling with PepSeq, a high-throughput screen that physically credentializes putative neoantigens based on binding affinity to patient-specific HLA class II proteins.\"},{\"question\":\"What efficacy results are reported for SNAP-TIL products in preclinical models?\",\"answer\":\"Using the SNAP platform, SNAP-TIL showed greater efficacy and selectivity than rapid expansion protocol controls, with tumor growth inhibition reported as 70% in melanoma and 50% in pancreatic patient-derived xenograft models.\"}]","Preclinical proof of concept for a personalized SNAP™-TIL (Specific Neo-Antigen Peptides-TIL) therapy platform | PDF",1790141844,45,4,[33,37,42,47],{"page_no":21,"url":34,"width":35,"height":36},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f80519dc9069a9ada49ceedfb55d16d.webp",983,1310,{"page_no":38,"url":39,"width":40,"height":41},2,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a0f4f05b743e97311f1cf0b574e8687.webp",982,1309,{"page_no":43,"url":44,"width":45,"height":46},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f917a36821f2db068a5b653f6a183b9.webp",981,1308,{"page_no":31,"url":48,"width":49,"height":50},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/36825843f61cf8fe757f65e89620ad2a.webp",980,1306,{"code":4,"msg":5,"data":52},[53,58,62,66,71,76,81,84,89,92,95],{"id":21,"doc_module":4,"doc_module_name":54,"category_name":55,"show_sort_weight":56,"slug":57},"Document","Story & Novel",90,"story-novel",{"id":38,"doc_module":4,"doc_module_name":54,"category_name":59,"show_sort_weight":60,"slug":61},"Literature",80,"literature",{"id":31,"doc_module":4,"doc_module_name":54,"category_name":63,"show_sort_weight":64,"slug":65},"Exam",70,"exam",{"id":67,"doc_module":4,"doc_module_name":54,"category_name":68,"show_sort_weight":69,"slug":70},5,"Comic",60,"comic",{"id":72,"doc_module":4,"doc_module_name":54,"category_name":73,"show_sort_weight":74,"slug":75},6,"Technology",50,"technology",{"id":77,"doc_module":4,"doc_module_name":54,"category_name":78,"show_sort_weight":79,"slug":80},7,"Healthcare",40,"healthcare",{"id":11,"doc_module":4,"doc_module_name":54,"category_name":12,"show_sort_weight":82,"slug":83},30,"research-report",{"id":85,"doc_module":4,"doc_module_name":54,"category_name":86,"show_sort_weight":87,"slug":88},9,"Religion & Spirituality",20,"religion-spirituality",{"id":87,"doc_module":4,"doc_module_name":54,"category_name":90,"show_sort_weight":87,"slug":91},"World Cup","world-cup",{"id":20,"doc_module":4,"doc_module_name":54,"category_name":93,"show_sort_weight":20,"slug":94},"Lifestyle","lifestyle",{"id":96,"doc_module":4,"doc_module_name":54,"category_name":97,"show_sort_weight":67,"slug":98},19,"General","general",{"code":4,"msg":100,"data":101},"ok",{"site_id":25,"language":24,"slug":102,"title":13,"keywords":103,"description":14,"schema_data":104,"social_meta":157,"head_meta":159,"extra_data":161,"updated_unix":162},"preclinical-proof-of-concept-for-a-personalized-snap-til-specific-neo-antigen-peptides-til-therapy-platform","",{"@graph":105,"@context":156},[106,119,139],{"@type":107,"itemListElement":108},"BreadcrumbList",[109,113,115,117],{"item":110,"name":111,"@type":112,"position":21},"https://docshare.wps.com","Home","ListItem",{"item":114,"name":54,"@type":112,"position":38},"https://docshare.wps.com/document/",{"item":116,"name":12,"@type":112,"position":43},"https://docshare.wps.com/document/research-report/",{"item":118,"name":13,"@type":112,"position":31},"https://docshare.wps.com/document/preclinical-proof-of-concept-for-a-personalized-snap-til-specific-neo-antigen-peptides-til-therapy-platform/360858/",{"url":118,"name":13,"@type":120,"image":121,"author":126,"headline":13,"publisher":128,"fileFormat":131,"inLanguage":24,"description":14,"dateModified":132,"datePublished":133,"encodingFormat":131,"isAccessibleForFree":134,"interactionStatistic":135},"DigitalDocument",{"url":122,"@type":123,"width":124,"height":125},"https://docshare.wps.com/thumbnails/preclinical-proof-of-concept-for-a-personalized-snap-til-specific-neo-antigen-peptides-til-therapy-platform/360858.png","ImageObject",300,407,{"name":9,"@type":127},"Person",{"url":110,"name":129,"@type":130},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":136,"interactionType":137,"userInteractionCount":20},"InteractionCounter",{"@type":138},"ViewAction",{"@type":140,"mainEntity":141},"FAQPage",[142,148,152],{"name":143,"@type":144,"acceptedAnswer":145},"What problem does the personalized SNAP™-TIL approach aim to solve in TIL therapy?","Question",{"text":146,"@type":147},"TIL responses depend on neoantigen recognition, but neoantigen-reactive T cells can be rare and exhausted in less immunogenic tumors. SNAP™ aims to improve enrichment for reactive neoantigens before expansion and reinfusion.","Answer",{"name":149,"@type":144,"acceptedAnswer":150},"How does SNAP™ technology validate and enrich neoantigen-specific TILs?",{"text":151,"@type":147},"SNAP™ combines advanced computational modeling with PepSeq, a high-throughput screen that physically credentializes putative neoantigens based on binding affinity to patient-specific HLA class II proteins.",{"name":153,"@type":144,"acceptedAnswer":154},"What efficacy results are reported for SNAP-TIL products in preclinical models?",{"text":155,"@type":147},"Using the SNAP platform, SNAP-TIL showed greater efficacy and selectivity than rapid expansion protocol controls, with tumor growth inhibition reported as 70% in melanoma and 50% in pancreatic patient-derived xenograft models.","https://schema.org",{"og:url":118,"og:type":158,"og:title":13,"og:site_name":129,"og:description":14},"article",{"robots":160,"canonical":118},"index,follow",{"doc_id":7,"site_id":25},1790211685]